November 14, 2026

To
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Bandra Kurla Complex,
Mumbai-400051

Symbol: ONYX

Dear Sir / Madam,

Sub: Outcome of the Board Meeting – Unaudited Financial Results for the half year ended September 30, 2026

Further to our letter dated November 04, 2026 and pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, November 14, 2026, inter-alia, considered and approved the Unaudited Financial Results of the Company for the half year ended September 30, 2026.

In this regard, we are enclosing herewith:

1. The Unaudited Financial Results of the Company for the half year ended September 30, 2026;

2. The Limited Review Report on Unaudited Financial Results of the Company for the half year ended September 30, 2026. A copy of the same is enclosed herewith.

The Unaudited financial results will be available on the Company's website i.e. www.onyxbiotec.com and on the website of the Stock Exchanges, https://www.nseindia.com/.

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No.CIR/CFD/CMD1/162/2019 dated December 24, 2019, the Board noted that there is no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offering (IPO) of the Company during the period September 30, 2026. Statement of Utilization of proceeds from Initial Public Offering (Equity Shares) is annexed herewith Annexure - A.

The meeting commenced at 4:00 p.m. and concluded at 4:20 p.m.

We request you to kindly take the above on records.

Yours faithfully
For Onyx Biotec Limited

HARSH MAHAJAN
Digitally signed by HARSH MAHAJAN
Date: 2026.11.14 16:50:54 +05'30'

Harsh Mahajan
Whole-time director & CFO
DIN: 09793917

R C A AND CO LLP

CHARTERED ACCOUNTANTS

712, New Delhi House, New Delhi House,
27 Barakhamba Road, New Delhi – 110001
Mobile: +91 78750 00059| Email: mayank.bansal099@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors
Onyx Biotec Limited

Sub: Limited Review Report on the Unaudited Standalone Financial Results for the Half year ended on September 30, 2026.

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Onyx Biotec Limited "the Company"** for the half year ended September 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant Circulars issued by SEBI from time to time.

2. This statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information" Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R C A AND CO LLP
Firm Registration Number: 011602N/N500350
Chartered Accountants

MAYANK BANSAL
Digitally signed by MAYANK BANSAL
Date: 2026.11.14 16:48:23 +05'30'

Mayank Bansal
Partner
Membership Number 550769

UDIN: 26550769OMSFXQ4809
Place of the Signature: Nalagarh
Date: 14 November 2026

ONYX BIOTEC LIMITED

CIN:L24230HP2005PLC028403

Regd. Office: Village Bir Plassi, Near Sainimajra, Ropar Nalagrh Road, Solan, Himachal Pradesh - 174101

Email: generalinfo@onyxbiotec.com Website:https://www.onyxbiotec.com

Statement Financial Results for the Half Year Ended September 30, 2026

(Rs in Lakhs Except EPS)

SI. No	Particulars	Half Year Ended			Year Ended
		30-Sep-26	31-Mar-26	30-Sep-25	31-Mar-26
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue**				
	a) Revenue from operations	4,340.86	3,488.44	3,458.50	6,946.94
	b) Other Income	38.90	20.64	23.82	44.46
	Total	**4,379.76**	**3,509.08**	**3,482.32**	**6,991.40**
2	**Expenditure**				
	a) Cost of material consumed	3,270.14	2,563.99	2,547.58	5,111.57
	b) (Increase)/decrease in stock-in-trade	(11.24)	(10.91)	64.63	53.71
	c) Employee benefits expense	429.58	455.88	404.83	860.70
	d) Depreciation, amortization & impairment expense	144.54	149.19	155.99	305.19
	e) Finance costs	54.99	66.21	54.94	121.14
	f) Other expenses	365.94	234.24	347.01	581.25
	Total Expenditure	**4,253.93**	**3,458.59**	**3,574.98**	**7,033.57**
3	**Profit before exceptional items and tax (1-2)**	**125.83**	**50.49**	**(92.66)**	**(42.16)**
4	**Exceptional Items**				-
5	**Profit for the period before Tax (3 - 4)**	**125.83**	**50.49**	**(92.66)**	**(42.16)**
6	Tax Expense - Current	59.38	5.42	-	5.42
	- Deferred Tax	(27.71)	(58.41)	(2.61)	(61.02)
	- Previous years	-	34.88	-	34.88
	Total Tax Expenses	**31.67**	**(18.11)**	**(2.61)**	**(20.72)**
7	**Net Profit/(Loss) after tax for the period (5 - 6)**	**94.16**	**68.60**	**(90.05)**	**(21.44)**
12	**Earnings Per Share (EPS)**				
	a) Basic & Diluted	0.52	0.38	(0.50)	(0.12)

Notes on standalone financial results

The Above results which are published in accordance with Regulations 33 of SEBI (Listing Obligation & Disclosure Requirements),2015 have been reviewed by the Audit Committee and approved by the Board of directors at their respective meeting held on 14th Day of November, 2026. The Financials results have been prepared in accordance with the accounting Standards ("AS") as prescribed under section 133 of the companies Act,2013 read with rule 7 of Companies (Accounts) Rules 2014 by the Ministry of Corporate Affairs and amendments thereof.

As per Ministry of Corporate Affairs Notification dated February 16, 2015. Companies whose securities are listed on SME Exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.

The figures for the corresponding previous period have been regrouped / reclassified wherever necessary.

As the Company collectively operates only in one business Segment, i.e. manufacturing of pharmaceutical products, hence, it is reporting its results in single Segment. Therefore, segment disclosure is not applicable.

The Company has made provision for doubtful debts amounting to INR 139.73 Lakhs during the half year ended 30 September 2026

The Earnings per share is calculated on the weighted average of the issued share capital by the company. Half yearly EPS is not annualised.

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/N500350

MAYANK BANSAL
Digitally signed by MAYANK BANSAL
Date: 2026.11.14 16:49:15 +05'30'

CA Mayank Bansal
Partner
Membership No: 550769
UDIN: 26550769OMSFXQ4809
Place: Nalagarh
Date: 14 November 2026

For and on behalf of the Board of Directors of
Onyx Biotec Limited

HARSH MAHAJAN
Digitally signed by HARSH MAHAJAN
Date: 2026.11.14 16:39:26 +05'30'

Harsh Mahajan
Whole Time Director & CFO
DIN: 09793917

ONYX BIOTEC LIMITED

CIN:L24230HP2005PLC028403

Regd. Office: Village Bir Plassi, Near Sainimajra, Ropar Nalagrh Road, Solan, Himachal Pradesh - 174101

Email: generalinfo@onyxbiotec.com Website:https://www.onyxbiotec.com

Standalone Statement of Assets and Liabilities (Rs. in Lakhs)

Particulars	As at Sep 30, 2026 Unaudited	As at Mar 31, 2026 Audited
EQUITY & LIABILITIES		
1. Shareholder's Fund		
(a) Share Capital	1,813.22	1,813.22
(b) Reserves & Surplus	3,821.72	3,727.56
	5,634.94	**5,540.78**
2. Non Current Liabilities		
(a) Long Term Borrowings	404.16	468.94
(b) Deferred Tax Liabilities (Net)	225.32	253.03
	629.48	**721.97**
3. Current Liabilities		
(a) Short Term Borrowings	677.15	1,048.19
(b) Trade Payables		
(i) total outstanding dues of micro enterprises and small enterprises; and	177.55	163.83
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises	1,935.71	1,600.80
(c) Other Current Liabilities	224.53	289.88
(d) Short Term Provisions	59.38	-
	3,074.32	**3,102.70**
TOTAL	**9,338.74**	**9,365.45**
ASSETS		
1. Non-Current Assets		
(a) Property, Plant & Equipments and Intangible Assets		
(i) Property, Plant & Equipments	3,680.38	3,915.96
(ii) Capital Work in Progress	622.94	367.56
(b) Other Non Current Assets	107.80	104.11
	4,411.12	**4,387.62**
2. Current Assets		
(a) Current Investments		
(b) Inventories	1,491.04	1,403.96
(c) Trade Receivable	2,573.10	2,599.80
(d) Cash & Cash Equivalents	113.80	403.74
(e) Short Term Loans & Advances	129.64	77.39
(f) Other Current Assets	620.04	492.93
	4,927.62	**4,977.83**
	9,338.74	**9,365.45**

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/N500350

MAYANK BANSAL Digitally signed by MAYANK BANSAL Date: 2026.11.14 16:49:47 +05'30'

CA Mayank Bansal
Partner
Membership No: 550769
UDIN: 26550769OMSFXQ4809
Place: Nalagarh
Date: 14 November 2026

For and on behalf of the Board of Directors
Onyx Biotec Limited

HARSH MAHAJAN Digitally signed by HARSH MAHAJAN Date: 2026.11.14 16:39:42 +05'30'

Harsh Mahajan
Whole Time Director & CFO
DIN: 09793917

ONYX BIOTEC LIMITED

CIN:L24230HP2005PLC028403

Regd. Office: Village Bir Plassi, Near Sainimajra, Ropar Nalagrh Road, Solan, Himachal Pradesh - 174101

Email: generalinfo@onyxbiotec.com Website:https://www.onyxbiotec.com

Standalone Statement of Cash Flow Statement for the half year ended September 30, 2026

	(Rs. in Lakhs) September 30, 2026	(Rs. in Lakhs) March 31, 2026
A Cash Flow from Operating activities		
Profit before tax	125.82	(42.16)
Adjustments for:		
Depreciation, amortization & impairment	144.54	305.19
Gain on sale of Fixed assets	(32.12)	-
Interest expenses	54.99	121.14
Interest income	(3.48)	(40.43)
Operating cash flows before working capital changes	**289.75**	**343.74**
Adjustments for changes in working capital:		
Change in trade receivables	26.71	(726.57)
Change in loans and advances and other assets	(179.35)	(145.95)
Change in non current assets	(3.70)	11.83
Change in inventories	(87.08)	206.03
Change in Provisions	-	9.51
Change in trade payables	348.63	91.49
Change in other liabilities	(65.35)	60.49
Cash used in operations	**329.61**	**(149.42)**
Net cash (used in) operating activities	**329.61**	**(149.42)**
B Cash flow from Investing activities		
Purchase of fixed assets including capital work in progress	(307.22)	(498.67)
Sale of fixed assets	175.00	-
Interest received	3.48	40.43
Net cash (used in) investing activities	**(128.73)**	**(458.25)**
C Cash flow from Financing activities		
Long term borrowings	(64.79)	(206.73)
Short term borrowings	(371.04)	478.08
Interest paid	(54.99)	(121.14)
Net cash flow from financing activities	**(490.82)**	**150.20**
Net (decrease) in cash and cash equivalents (A+B+C)	**(289.94)**	**(457.47)**
Cash and cash equivalents at beginning of period	403.74	861.21
Cash and cash equivalents at end of period	**113.80**	**403.74**

For R C A AND CO LLP
Chartered Accountants
Firm Registration No: 011602N/N500350

MAYANK BANSAL
Digitally signed by MAYANK BANSAL
Date: 2026.11.14 16:50:15 +05'30'

CA Mayank Bansal
Partner
Membership No: 550769
UDIN: 26550769OMSFXQ4809
Place: Nalagarh
Date: 14 November 2026

For and on behalf of the Board of Directors of
Onyx Biotec Limited

HARSH MAHAJAN
Digitally signed by HARSH MAHAJAN
Date: 2026.11.14 16:39:54 +05'30'

Harsh Mahajan
Whole Time Director & CFO
DIN: 09793917

R C A AND CO LLP

CHARTERED ACCOUNTANTS

712, New Delhi House, New Delhi House,
27 Barakhamba Road, New Delhi – 110001
Mobile: +91 78750 00059| Email: mayank.bansal099@gmail.com

To,

Audit Committee/ Board of Directors,

Onyx Biotec Limited,

Regd. Office: Village Bir Plassi, Near Sainimajra,

Ropar Nalagrh Road, Solan, Himachal Pradesh - 174101

Sub: Statement of Deviation/Variation in utilisation of funds raised through Initial Public offering

Dear Sir,

On the basis of examination of books of accounts and other documents produced before us for our verification and information, and explanations given to us by "ONYX BIOTEC LIMITED" ("the company"), we certify that the Company has utilized the following amount of IPO proceeds as per the "objects of the issue" stated in the prospectus dated November 19, 2024, filed for the issuance of shares by the Company:

Name of listed entity	**Onyx Biotec Limited**
Mode of Fund Raising	IPO
Date of Raising Funds	22 November 2024
Amount Raised (Net of IPO expenses)	Rs. 2538.02 Lakhs*
Report filed for half year ended	30th September, 2026
Monitoring Agency	NA
Monitoring Agency Name, if applicable	NA
Is there a Deviation /Variation in use of funds raised	NA
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	NA
Comments of the Chartered accountants, if Any	No
Objects for which funds have been raised and where there has been a deviation, in the following table	Object of the Issue was: 1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use 2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections 3. Prepayment or repayment of all or a portion of certain loans availed by our Company 4. General corporate purposes We hereby confirm that there was no deviation from the objects.

R C A AND CO LLP

CHARTERED ACCOUNTANTS

712, New Delhi House, New Delhi House,
27 Barakhamba Road, New Delhi – 110001
Mobile: +91 78750 00059| Email: mayank.bansal099@gmail.com

Original Object	Modified Object, if any	Original Allocation (INR Lakhs)	Allocation Modified Allocation, if any (INR Lakhs)	Fund Utilized (INR Lakhs)	Amount of Deviation/Variation For the quarter According to applicable object	Remarks if Any
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use	**NA**	607.70	**NA**	573.30	Nil	Advance of INR 22.07 lakhs has been paid upto 30th September and bills will be received once work is complete
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections	**NA**	124.05	**NA**	91.55	Nil	-
Prepayment or repayment of all or a portion of certain loans availed by our Company	**NA**	**1200**	**NA**	**1200**	Nil	**-**
General corporate purposes	**Yes**	**600**	**606.27***	**599.42**	Nil	**Refer Note**
Total		**2531.75**	**2538.02**	**2464.27**	Nil	

Note

*During the Half ended 30 September 2026, the originally estimated issue expenses amounting to ₹402.35 lakhs have been actualized to ₹396.08 Lakhs, as per the actual invoices against original estimated issue expenses. Accordingly, net proceeds have increased from ₹2531.75 Lakhs to ₹2538.02 Lakhs and funds utilization under object "General Corporate purposes" have increased to ₹606.27 Lakhs from previously estimated amount of ₹600 Lakhs.

* Unutilized amount of ₹ 67.00 lakhs has been invested/parked in fixed deposit with HDFC Bank

*Unutilized amount of ₹ 6.85 lakhs has been separately kept in account created with HDFC Bank for IPO purpose.

R C A AND CO LLP

CHARTERED ACCOUNTANTS

712, New Delhi House, New Delhi House,
27 Barakhamba Road, New Delhi – 110001
Mobile: +91 78750 00059| Email: mayank.bansal099@gmail.com

For R C A AND CO LLP
Firm Registration Number: 011602N/N500350
Chartered Accountants

Mayank Bansal
Partner
Membership Number 550769
UDIN: 26550769ZPREFX8683
Place of the Signature: Nalagarh
Date: 14 November 2026